Literature DB >> 12452938

Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.

E Domènech1, E Garcia-Planella, I Bernal, M Rosinach, E Cabré, L Fluvià, J Boix, M A Gassull.   

Abstract

BACKGROUND: Intravenous ciclosporin is considered to be the only alternative to avoid surgery in severe, steroid-refractory ulcerative colitis. In responders, some authors recommend a switch to oral ciclosporin to act as a 'bridge' until the therapeutic action of azathioprine is achieved for maintenance treatment. AIM: To report the short- and long-term outcome of intravenous ciclosporin-responsive ulcerative colitis patients treated with oral azathioprine without oral ciclosporin.
METHODS: The records of all patients treated with intravenous ciclosporin for severe, steroid-refractory ulcerative colitis were reviewed. Responders following treatment with azathioprine but without oral ciclosporin as maintenance therapy were included. Patients with colonic cytomegalovirus infection and/or follow-up of less than 1 year were excluded.
RESULTS: Twenty-seven patients were included. Steroids were discontinued in 24 (89%). The median follow-up was 36 months. Eighteen (75%) patients presented mild or moderate relapses, which were easily managed with salicylates or steroids. Cumulative probabilities of relapse were 42%, 72% and 77% at 1, 3 and 5 years, respectively. Eleven (40.7%) patients underwent elective colectomy. Cumulative probabilities of colectomy were 29%, 35% and 42% at 1, 3 and 5 years, respectively. No opportunistic infections were observed.
CONCLUSIONS: Oral azathioprine seems to be enough to maintain long-term remission induced by intravenous ciclosporin in patients with steroid-refractory ulcerative colitis. The 'bridging step' with oral ciclosporin may not be necessary in this subset of patients, although a randomized controlled trial is warranted to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452938     DOI: 10.1046/j.1365-2036.2002.01385.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.

Authors:  Ken Fukunaga; Kazuko Nagase; Takeshi Kusaka; Nobuyuki Hida; Yoshio Ohda; Koji Yoshida; Katsuyuki Tozawa; Koji Kamikozuru; M Iimuro; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

2.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

3.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

4.  Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Authors:  Parita Patel; Andres Yarur; Sushila Dalal; Atsuhi Sakuraba; David T Rubin; Stephen B Hanauer; Ira Hanan; Laura H Raffals; Russell D Cohen; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

5.  Predictors of clinical response to systemic steroids in active ulcerative colitis.

Authors:  Isabel Bernal; Míriam Mañosa; Eugeni Domènech; Esther Garcia-Planella; Mercè Navarro; Vicente Lorenzo-Zúñiga; Eduard Cabré; Miquel Angel Gassull
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

6.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 7.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 8.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Authors:  Antje Timmer; Petrease H Patton; Nilesh Chande; John W D McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-18

Review 9.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.

Authors:  I Ordás; E Domènech; M Mañosa; V García-Sánchez; E Iglesias-Flores; M Peñalva; A Cañas-Ventura; O Merino; F Fernández-Bañares; F Gomollón; M Vera; A Gutiérrez; E Garcia-Planella; M Chaparro; M Aguas; E Gento; F Muñoz; M Aguirresarobe; C Muñoz; L Fernández; X Calvet; C E Jiménez; M A Montoro; A Mir; M L De Castro; M F García-Sepulcre; F Bermejo; J Panés; M Esteve
Journal:  Am J Gastroenterol       Date:  2017-07-04       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.